- Full Year 2024 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2024
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2024
- Q3 2024 Eisai Co Ltd Earnings Presentation TranscriptFeb 06, 2024
- Eisai Co Ltd Launch of LEQEMBI in Japan TranscriptDec 13, 2023
- Q2 2024 Eisai Co Ltd Earnings Presentation TranscriptNov 07, 2023
- Q1 2024 Eisai Co Ltd Earnings Presentation TranscriptAug 02, 2023
- Eisai Co Ltd Media and Investor Conference TranscriptJul 07, 2023
- Full Year 2023 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2023
- Eisai Co Ltd Information Meeting TranscriptMar 10, 2023
- Q3 2023 Eisai Co Ltd Earnings Call TranscriptFeb 06, 2023€52.72 (-4.97%)Earnings
- Eisai Co Ltd Approach to US Pricing for LEQEMBI Briefing TranscriptJan 07, 2023
- Eisai Co Ltd Clarity AD Study Briefing TranscriptNov 30, 2022
- Q2 2023 Eisai Co Ltd Earnings Call TranscriptNov 07, 2022€59.02 (-1.99%)Earnings
- Eisai Co Ltd Lecanemab Phase 3 Study Met Primary Endpoint Call TranscriptSep 28, 2022
- Q1 2023 Eisai Co Ltd Earnings Call TranscriptAug 05, 2022€43.78 (-1.42%)Earnings
- Full Year 2022 Eisai Co Ltd Earnings Presentation TranscriptMay 13, 2022
- Eisai Co Ltd Information Meeting TranscriptMar 16, 2022
- Q3 2022 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2022€44.4 (-1.33%)Earnings
- Q2 2022 Eisai Co Ltd Earnings Call TranscriptNov 01, 2021€63 (+5.00%)Earnings
- Q1 2022 Eisai Co Ltd Earnings Call TranscriptAug 04, 2021€69.5Earnings
- Eisai Co Ltd FDA Grants Accelerated Approval for ADUHELM Presentation TranscriptJun 09, 2021
- Full Year 2021 Eisai Co Ltd Earnings Call TranscriptMay 12, 2021€52.5 (-0.94%)Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 26, 2021
- Q3 2021 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2021€60 (-0.83%)Earnings
- Q2 2021 Eisai Co Ltd Earnings Call TranscriptNov 05, 2020€94 (+24.50%)Earnings
- Q1 2021 Eisai Co Ltd Earnings Call TranscriptAug 03, 2020€70 (+2.94%)Earnings
- Full Year 2020 Eisai Co Ltd Earnings Call TranscriptMay 13, 2020€63.5 (-1.55%)Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 06, 2020
- Q3 2020 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptJan 31, 2020
- Full Year 2019 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptMay 13, 2019
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2019
Eisai Co Ltd Approach to US Pricing for LEQEMBI Briefing Transcript
Hello, everyone. Now we'd like to start Eisai's conference for media and investors. Thank you very much for joining today out of your very busy schedule at the beginning of the new year in spite of the short notice. Today, Japan time and on January 6 U.S. time, treatment for AD, lecanemab, or LEQEMBI as its U.S. brand name was granted accelerated approval for U.S. FDA.
This morning at 4:30 a.m. JST, we issued a press release related to the accelerated approval and the statement on our U.S. pricing and the rationale behind, and LEQEMBI safety statement from the Global Safety Officer.
At 1:30 p.m., we filed a partial change application from the accelerated approval to full traditional approval. In this conference today, we'd like to explain our thinking behind the pricing for LEQEMBI. Today's conference is organized, both on-site and online in a hybrid fashion. We thank on-site participants for wearing their face mask to prevent COVID-19 infections. Those joining on site can find in your handout 4 takes of documents, including a release and statements and the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)